📋 Tender Overview
Contract awarded for Framework agreement for oncological medicines 16 batches lot-0001, title: cetuximab sol. perf. 5mg/ml - 20 ml, description: cetuximab sol. perf. 5mg/ml - 20 ml minimum quantity framework agreement 10 maximum quantity framework agreement 150 lot-0002, title: pertuzumab conc. for sol./perf. 420mg/14 ml, description: pertuzumab conc. for sol./perf. 420mg/14 ml minimum quantity framework agreement 10 maximum quantity framework agreement 300 lot-0003, title: cabazitaxel conc. + solv. /sol. perf. 60 mg (1.5ml concentrate + 4.5ml solvent), description: cabazitaxel conc. + solv. /sol. perf. 60 mg (1.5ml concentrate + 4.5ml solvent) minimum quantity framework agreement 10 maximum quantity framework agreement 50 lot-0004, title: docetaxel conc. for sol. / perf. 20mg/ml - 7ml, description: docetaxel conc. for sol. / perf. 20mg/ml - 7ml minimum quantity framework agreement 10 maximum quantity framework agreement 300 lot-0005, title: paclitaxel conc. for sol. perf. 6mg/ml - 25 ml, description: paclitaxel conc. for sol. perf. 6mg/ml - 25 ml minimum quantity framework agreement 30 maximum quantity framework agreement 350 lot-0006, title: docetaxel conc. for sol. / perf. 20mg/ml - 4ml, description: docetaxel conc. for sol. / perf. 20mg/ml - 4ml minimum quantity framework agreement 10 maximum quantity framework agreement 300 lot-0007, title: doxorubicin powder + mixture for conc. for liposomal disp. for perf. (liposomal vial + tampon solution vial) 50mg/vial, description: doxorubicin powder + mixture for conc. for liposomal disp. for perf. (liposomal vial + tampon solution vial) 50mg/vial minimum quantity framework agreement 20 maximum quantity framework agreement 200 lot-0009, title: epirubicin solution inj / perf. 2mg/ml - 25 ml, description: epirubicin solution inj / perf. 2mg/ml - 25 ml minimum quantity framework agreement 10 maximum quantity framework agreement 200 lot-0010, title: oxaliplatin liof. for sol. / perf. 5mg/ml - 20 ml / 100 mg, description: oxaliplatin liof. for sol. / perf. 5mg/ml - 20 ml / 100 mg minimum quantity framework agreement 10 maximum quantity framework agreement 500 lot-0012, title: carboplatin conc. for sol. / perf. 10mg/ml - 15ml, description: carboplatin conc. for sol. / perf. 10mg/ml - 15ml minimum quantity framework agreement 10 maximum quantity framework agreement 300 lot-0013, title: fluorouracil / conc. for sol. inj. / perf. 50mg/ml-100 ml, description: fluorouracil / conc. for sol. inj. / perf. 50mg/ml-100 ml minimum quantity framework agreement 10 maximum quantity framework agreement 400 lot-0014, title: gemcitabine powder for sol. perf. 100mg/ml – 10 ml (1000 mg), description: gemcitabine powder for sol. perf. 100mg/ml – 10 ml (1000 mg) minimum quantity framework agreement 10 maximum quantity framework agreement 200 lot-0015, title: etoposide conc. for sol. / perf. 20 mg/ml-10 ml, description: etoposide conc. for sol. / perf. 20 mg/ml-10 ml minimum quantity framework agreement 10 maximum quantity framework agreement 200 lot-0016, title: pemetrexed powder for sol. perf. 25mg/ml-20 ml 500 mg, description: pemetrexed powder for sol. perf. 25mg/ml-20 ml 500 mg minimum quantity framework agreement 10 maximum quantity framework agreement 200 estimated value excluding vat: 25246.00 ron.Framework agreement for oncological medicines 16 batches